{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:29:06Z","timestamp":1794544146652,"version":"4.9.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007116","name":"Indian Institute of Science Education and Research Pune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007116","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.compbiomed.2021.105183","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T20:30:50Z","timestamp":1640723450000},"page":"105183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7363-7091","authenticated-orcid":false,"given":"Abhik Kumar","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth Sarthi","family":"Sen Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj Kumar","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyaranjan","family":"Biswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uddipan","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1713-8220","authenticated-orcid":false,"given":"Malay Kumar","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.compbiomed.2021.105183_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiomed.2021.105183_bib2","first-page":"1","article-title":"Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19","author":"Muralidharan","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"6","key":"10.1016\/j.compbiomed.2021.105183_bib3","doi-asserted-by":"crossref","first-page":"105964","DOI":"10.1016\/j.ijantimicag.2020.105964","article-title":"Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage","volume":"55","author":"Olsen","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"7798","key":"10.1016\/j.compbiomed.2021.105183_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.compbiomed.2021.105183_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40203-021-00105-x","article-title":"In silico studies of Potency and safety assessment of selected trial drugs for the treatment of COVID-19","volume":"9","author":"Adegbola","year":"2021","journal-title":"In Silico Pharmacol"},{"issue":"5","key":"10.1016\/j.compbiomed.2021.105183_bib6","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1742-4658.2006.05130.x","article-title":"The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain","volume":"273","author":"Shi","year":"2006","journal-title":"FEBS J."},{"key":"10.1016\/j.compbiomed.2021.105183_bib7","series-title":"Structure of M Pro from COVID-19 Virus and Discovery of its Inhibitors","author":"Jin","year":"2020"},{"issue":"9","key":"10.1016\/j.compbiomed.2021.105183_bib8","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.compbiomed.2021.105183_bib9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s13238-011-1034-1","article-title":"Activation and maturation of SARS-CoV main protease","volume":"2","author":"Xia","year":"2011","journal-title":"Protein Cell"},{"issue":"17","key":"10.1016\/j.compbiomed.2021.105183_bib10","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1021\/jm060207o","article-title":"Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe Acute respiratory Syndrome coronavirus main protease","volume":"49","author":"Lu","year":"2006","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.compbiomed.2021.105183_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"issue":"18","key":"10.1016\/j.compbiomed.2021.105183_bib12","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J."},{"key":"10.1016\/j.compbiomed.2021.105183_bib13","doi-asserted-by":"crossref","first-page":"622898","DOI":"10.3389\/fchem.2021.622898","article-title":"Structural basis of potential inhibitors targeting SARS-CoV-2 main protease","volume":"9","author":"Mengist","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.compbiomed.2021.105183_bib14","first-page":"1","article-title":"Molecular docking and ADMET studies of Allium cepa, Azadirachta indica and Xylopia aethiopica isolates as potential anti-viral drugs for Covid-19","author":"Adegbola","year":"2021","journal-title":"Virusdisease"},{"issue":"8","key":"10.1016\/j.compbiomed.2021.105183_bib15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.compbiomed.2021.105183_bib16","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","article-title":"Broad spectrum antiviral agent niclosamide and its therapeutic potential","volume":"6","author":"Xu","year":"2020","journal-title":"ACS Infect. Dis."},{"issue":"6489","key":"10.1016\/j.compbiomed.2021.105183_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"52","key":"10.1016\/j.compbiomed.2021.105183_bib18","doi-asserted-by":"crossref","first-page":"23544","DOI":"10.1002\/anie.202010316","article-title":"Allosteric inhibition of the SARS-CoV-2 main protease: insights from mass spectrometry based assays","volume":"59","author":"El-Baba","year":"2020","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"3","key":"10.1016\/j.compbiomed.2021.105183_bib19","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1006\/jmbi.1993.1626","article-title":"Comparative protein modelling by satisfaction of spatial restraints","volume":"234","author":"\u0160ali","year":"1993","journal-title":"J. Mol. Biol."},{"issue":"2","key":"10.1016\/j.compbiomed.2021.105183_bib20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1747-0285.2012.01406.x","article-title":"Molecular docking and dynamics simulation, receptor-based hypothesis: application to identify novel sirtuin 2 inhibitors","volume":"80","author":"Sakkiah","year":"2012","journal-title":"Chem. Biol. Drug Des."},{"issue":"7","key":"10.1016\/j.compbiomed.2021.105183_bib21","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1080\/07391102.2019.1624296","article-title":"Homology modeling, docking and structure-based virtual screening for new inhibitor identification of Klebsiella pneumoniae heptosyltransferase-III","volume":"38","author":"Panda","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"D1","key":"10.1016\/j.compbiomed.2021.105183_bib22","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"10.1016\/j.compbiomed.2021.105183_bib23","doi-asserted-by":"crossref","first-page":"D1137","DOI":"10.1093\/nar\/gkx1088","article-title":"SuperDRUG2: a one stop resource for approved\/marketed drugs","volume":"46","author":"Siramshetty","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.compbiomed.2021.105183_bib24","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","author":"Trott","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.compbiomed.2021.105183_bib25","series-title":"Chemical Biology","first-page":"243","article-title":"Small-molecule library screening by docking with PyRx","author":"Dallakyan","year":"2015"},{"key":"10.1016\/j.compbiomed.2021.105183_bib26","doi-asserted-by":"crossref","first-page":"114375","DOI":"10.1016\/j.molliq.2020.114375","article-title":"Computer-aided discovery of bis-indole derivatives as multi-target drugs against cancer and bacterial infections: DFT, docking, virtual screening, and molecular dynamics studies","volume":"320","author":"Gupta","year":"2020","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.compbiomed.2021.105183_bib27","doi-asserted-by":"crossref","first-page":"116851","DOI":"10.1016\/j.molliq.2021.116851","article-title":"Inhibitors of Plasmepsin X Plasmodium falciparum: structure-based pharmacophore generation and molecular dynamics simulation","author":"Panda","year":"2021","journal-title":"J. Mol. Liq."},{"issue":"1","key":"10.1016\/j.compbiomed.2021.105183_bib28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/acs.jcim.9b00778","article-title":"Autodock Vina adopts more accurate binding poses but Autodock 4 forms better binding affinity","volume":"60","author":"Nguyen","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.compbiomed.2021.105183_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1\u20132","author":"Abraham","year":"2015","journal-title":"Software"},{"issue":"13","key":"10.1016\/j.compbiomed.2021.105183_bib30","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/jcc.20090","article-title":"A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6","volume":"25","author":"Oostenbrink","year":"2004","journal-title":"J. Comput. Chem."},{"issue":"19","key":"10.1016\/j.compbiomed.2021.105183_bib31","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1063\/1.470117","article-title":"A smooth particle mesh Ewald method","volume":"103","author":"Essmann","year":"1995","journal-title":"J. Chem. Phys."},{"issue":"12","key":"10.1016\/j.compbiomed.2021.105183_bib32","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","article-title":"LINCS: a linear constraint solver for molecular simulations","volume":"18","author":"Hess","year":"1997","journal-title":"J. Comput. Chem."},{"issue":"1","key":"10.1016\/j.compbiomed.2021.105183_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"10.1016\/j.compbiomed.2021.105183_bib34","first-page":"1","article-title":"Screening and molecular characterization of lethal mutations of human homogentisate 1, 2 dioxigenase","author":"Sen Gupta","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.compbiomed.2021.105183_bib35","first-page":"1","article-title":"Anti-HIV potential of diarylpyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors: design, synthesis, docking, TOPKAT analysis and molecular dynamics simulations","author":"Singh","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"11","key":"10.1016\/j.compbiomed.2021.105183_bib36","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/14786440109462720","article-title":"LIII. On lines and planes of closest fit to systems of points in space","volume":"2","author":"Pearson","year":"1901","journal-title":"The London, Edinburgh, and Dublin Philosophical Magazine and Journal of Science"},{"issue":"6","key":"10.1016\/j.compbiomed.2021.105183_bib37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1037\/h0071325","article-title":"Analysis of a complex of statistical variables into principal components","volume":"24","author":"Hotelling","year":"1933","journal-title":"J. Educ. Psychol."},{"issue":"24","key":"10.1016\/j.compbiomed.2021.105183_bib38","doi-asserted-by":"crossref","first-page":"245102","DOI":"10.1063\/1.2945165","article-title":"Construction of the free energy landscape of biomolecules via dihedral angle principal component analysis","volume":"128","author":"Altis","year":"2008","journal-title":"J. Chem. Phys."},{"issue":"7","key":"10.1016\/j.compbiomed.2021.105183_bib39","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1021\/ci500020m","article-title":"g_mmpbsa \u2014a GROMACS tool for high-throughput MM-PBSA calculations","volume":"54","author":"Kumari","year":"2014","journal-title":"J. Chem. Inf. Model."},{"issue":"10","key":"10.1016\/j.compbiomed.2021.105183_bib40","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/bioinformatics\/bty879","article-title":"farPPI: a webserver for accurate prediction of protein-ligand binding structures for small-molecule PPI inhibitors by MM\/PB(GB)SA methods","volume":"35","author":"Wang","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.compbiomed.2021.105183_bib41","series-title":"Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro","author":"Gammeltoft","year":"2020"},{"key":"10.1016\/j.compbiomed.2021.105183_bib42","series-title":"The in Vitro Antiviral Activity of the Anti-hepatitis C Virus (HCV) Drugs Daclatasvir and Sofosbuvir against SARS-CoV-2","author":"Sacramento","year":"2020"},{"issue":"2","key":"10.1016\/j.compbiomed.2021.105183_bib43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12072-016-9776-8","article-title":"Sofosbuvir\/velpatasvir: a pangenotypic drug to simplify HCV therapy","volume":"11","author":"Lee","year":"2017","journal-title":"Hepatol Int"},{"issue":"5","key":"10.1016\/j.compbiomed.2021.105183_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02084-16","article-title":"Preclinical pharmacokinetics and first-in-human pharmacokinetics, safety, and tolerability of velpatasvir, a pangenotypic hepatitis C virus NS5A inhibitor, in healthy subjects","volume":"61","author":"Mogalian","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.compbiomed.2021.105183_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/467869","article-title":"Hepatitis C virus NS3 inhibitors: current and future perspectives","volume":"2013","author":"Salam","year":"2013","journal-title":"BioMed Res. Int."},{"issue":"9973","key":"10.1016\/j.compbiomed.2021.105183_bib46","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","volume":"385","author":"Lawitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.compbiomed.2021.105183_bib47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coviro.2019.01.006","article-title":"Baloxavir marboxil: the new influenza drug on the market","volume":"35","author":"O'Hanlon","year":"2019","journal-title":"Curr Opin Virol"},{"issue":"8","key":"10.1016\/j.compbiomed.2021.105183_bib48","first-page":"951","article-title":"Danoprevir, a small-molecule NS3\/4A protease inhibitor for the potential oral treatment of HCV infection","volume":"11","author":"Deutsch","year":"2010","journal-title":"Curr. Opin. Invest. Drugs"},{"issue":"1","key":"10.1016\/j.compbiomed.2021.105183_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/srep04765","article-title":"Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA","volume":"4","author":"Ascher","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiomed.2021.105183_bib50","series-title":"Nelfinavir Inhibits Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Vitro","author":"Yamamoto","year":"2020"},{"key":"10.1016\/j.compbiomed.2021.105183_bib51","first-page":"1","article-title":"Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-\u03b1 with in-vitro effective drug ivermectin","author":"Sen Gupta","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.compbiomed.2021.105183_bib52","series-title":"Evaluation of 19 Antiviral Drugs against SARS-CoV-2 Infection","author":"Liu","year":"2020"},{"issue":"12","key":"10.1016\/j.compbiomed.2021.105183_bib53","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1021\/acs.jcim.0c00491","article-title":"Computational determination of potential inhibitors of SARS-CoV-2 main protease","volume":"60","author":"Ngo","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.compbiomed.2021.105183_bib54","doi-asserted-by":"crossref","first-page":"105055","DOI":"10.1016\/j.antiviral.2021.105055","article-title":"Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors","volume":"189","author":"Milani","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.compbiomed.2021.105183_bib55","doi-asserted-by":"crossref","first-page":"105631","DOI":"10.1016\/j.ejps.2020.105631","article-title":"Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial","volume":"157","author":"Lou","year":"2021","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.compbiomed.2021.105183_bib56","series-title":"Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking","author":"Chang","year":"2020"},{"issue":"5","key":"10.1016\/j.compbiomed.2021.105183_bib57","doi-asserted-by":"crossref","first-page":"105955","DOI":"10.1016\/j.ijantimicag.2020.105955","article-title":"The epidemiology, diagnosis and treatment of COVID-19","volume":"55","author":"Zhai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.compbiomed.2021.105183_bib58","doi-asserted-by":"crossref","first-page":"AAC0268020","DOI":"10.1128\/AAC.02680-20","article-title":"Hepatitis C virus protease inhibitors show differential efficacy and interactions with remdesivir for treatment of SARS-CoV-2 in vitro","author":"Gammeltoft","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.compbiomed.2021.105183_bib59","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jac\/dkab072","article-title":"In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19","volume":"76","author":"Sacramento","year":"2021","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001048252100977X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001048252100977X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:54:44Z","timestamp":1762116884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001048252100977X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":59,"alternative-id":["S001048252100977X"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2021.105183","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv.12278066.v2","asserted-by":"object"}]},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2021.105183","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105183"}}